168 related articles for article (PubMed ID: 17037556)
1. SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry.
Huang IC; Bosch BJ; Li W; Farzan M; Rottier PM; Choe H
Adv Exp Med Biol; 2006; 581():335-8. PubMed ID: 17037556
[No Abstract] [Full Text] [Related]
2. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.
Huang IC; Bosch BJ; Li F; Li W; Lee KH; Ghiran S; Vasilieva N; Dermody TS; Harrison SC; Dormitzer PR; Farzan M; Rottier PJ; Choe H
J Biol Chem; 2006 Feb; 281(6):3198-203. PubMed ID: 16339146
[TBL] [Abstract][Full Text] [Related]
3. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63.
Glowacka I; Bertram S; Herzog P; Pfefferle S; Steffen I; Muench MO; Simmons G; Hofmann H; Kuri T; Weber F; Eichler J; Drosten C; Pöhlmann S
J Virol; 2010 Jan; 84(2):1198-205. PubMed ID: 19864379
[TBL] [Abstract][Full Text] [Related]
4. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.
Li W; Sui J; Huang IC; Kuhn JH; Radoshitzky SR; Marasco WA; Choe H; Farzan M
Virology; 2007 Oct; 367(2):367-74. PubMed ID: 17631932
[TBL] [Abstract][Full Text] [Related]
5. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.
Hofmann H; Pyrc K; van der Hoek L; Geier M; Berkhout B; Pöhlmann S
Proc Natl Acad Sci U S A; 2005 May; 102(22):7988-93. PubMed ID: 15897467
[TBL] [Abstract][Full Text] [Related]
6. Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors.
Hofmann H; Simmons G; Rennekamp AJ; Chaipan C; Gramberg T; Heck E; Geier M; Wegele A; Marzi A; Bates P; Pöhlmann S
J Virol; 2006 Sep; 80(17):8639-52. PubMed ID: 16912312
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.
Zhao X; Guo F; Comunale MA; Mehta A; Sehgal M; Jain P; Cuconati A; Lin H; Block TM; Chang J; Guo JT
Antimicrob Agents Chemother; 2015 Jan; 59(1):206-16. PubMed ID: 25348530
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis of SARS-associated coronavirus spike glycoprotein.
Simmons G; Rennekamp AJ; Bates P
Adv Exp Med Biol; 2006; 581():235-40. PubMed ID: 17037535
[No Abstract] [Full Text] [Related]
9. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds.
Haga S; Nagata N; Okamura T; Yamamoto N; Sata T; Yamamoto N; Sasazuki T; Ishizaka Y
Antiviral Res; 2010 Mar; 85(3):551-5. PubMed ID: 19995578
[TBL] [Abstract][Full Text] [Related]
10. Interaction between the spike protein of human coronavirus NL63 and its cellular receptor ACE2.
Pöhlmann S; Gramberg T; Wegele A; Pyrc K; van der Hoek L; Berkhout B; Hofmann H
Adv Exp Med Biol; 2006; 581():281-4. PubMed ID: 17037543
[No Abstract] [Full Text] [Related]
11. Insights from the association of SARS-CoV S-protein with its receptor, ACE2.
Li W; Choe H; Farzan M
Adv Exp Med Biol; 2006; 581():209-18. PubMed ID: 17037532
[No Abstract] [Full Text] [Related]
12. Infection of human airway epithelia by SARS coronavirus is associated with ACE2 expression and localization.
Jia HP; Look DC; Hickey M; Shi L; Pewe L; Netland J; Farzan M; Wohlford-Lenane C; Perlman S; McCray PB
Adv Exp Med Biol; 2006; 581():479-84. PubMed ID: 17037581
[No Abstract] [Full Text] [Related]
13. Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.
Kuhn JH; Li W; Radoshitzky SR; Choe H; Farzan M
Antivir Ther; 2007; 12(4 Pt B):639-50. PubMed ID: 17944271
[TBL] [Abstract][Full Text] [Related]
14. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2.
Mathewson AC; Bishop A; Yao Y; Kemp F; Ren J; Chen H; Xu X; Berkhout B; van der Hoek L; Jones IM
J Gen Virol; 2008 Nov; 89(Pt 11):2741-2745. PubMed ID: 18931070
[TBL] [Abstract][Full Text] [Related]
15. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus.
Nagata N; Iwata N; Hasegawa H; Fukushi S; Yokoyama M; Harashima A; Sato Y; Saijo M; Morikawa S; Sata T
J Virol; 2007 Feb; 81(4):1848-57. PubMed ID: 17151094
[TBL] [Abstract][Full Text] [Related]
16. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy.
Qu XX; Hao P; Song XJ; Jiang SM; Liu YX; Wang PG; Rao X; Song HD; Wang SY; Zuo Y; Zheng AH; Luo M; Wang HL; Deng F; Wang HZ; Hu ZH; Ding MX; Zhao GP; Deng HK
J Biol Chem; 2005 Aug; 280(33):29588-95. PubMed ID: 15980414
[TBL] [Abstract][Full Text] [Related]
17. The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
Du L; He Y; Zhou Y; Liu S; Zheng BJ; Jiang S
Nat Rev Microbiol; 2009 Mar; 7(3):226-36. PubMed ID: 19198616
[TBL] [Abstract][Full Text] [Related]
18. Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction.
Lin HX; Feng Y; Wong G; Wang L; Li B; Zhao X; Li Y; Smaill F; Zhang C
J Gen Virol; 2008 Apr; 89(Pt 4):1015-1024. PubMed ID: 18343844
[TBL] [Abstract][Full Text] [Related]
19. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease.
Bertram S; Glowacka I; Müller MA; Lavender H; Gnirss K; Nehlmeier I; Niemeyer D; He Y; Simmons G; Drosten C; Soilleux EJ; Jahn O; Steffen I; Pöhlmann S
J Virol; 2011 Dec; 85(24):13363-72. PubMed ID: 21994442
[TBL] [Abstract][Full Text] [Related]
20. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
Yi CE; Ba L; Zhang L; Ho DD; Chen Z
J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
